The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwMDS 2025 | Will clinical decision-making be entirely data-driven in the future?
In this interview, Adrián Mosquera Orgueira, MD, PhD, Santiago Clinic Hospital CHUS, Santiago, Spain, comments on the potential impact of artificial intelligence (AI) on prognostic scoring systems for myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs), suggesting that future models will be complex, multimodal, and collaborative between medical expertise and machine learning. Dr Mosquera Orgueira believes that AI will not replace human expertise entirely, but rather augment it, enriching clinical decision-making. This interview took place at the 3rd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) 2025, held in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think we are moving towards data-driven medicine, so I believe we are going to have more complex and more comprehensive multimodal risk models, which might not only be directed towards the whole MDS/MPN community of patients, but might also help you identify patients based on their response to different therapies. And I think that’s the way we should move. So it’s going to be always a complex collaboration between medical expertise and AI...
I think we are moving towards data-driven medicine, so I believe we are going to have more complex and more comprehensive multimodal risk models, which might not only be directed towards the whole MDS/MPN community of patients, but might also help you identify patients based on their response to different therapies. And I think that’s the way we should move. So it’s going to be always a complex collaboration between medical expertise and AI. I’m not so sure it will actually be fully data-driven, but I believe it will heavily enrich our decision-making. Actually, there are some examples in the United States with collaborations in decision-making between clinical doctors using generative AI tools for medicine and clinical doctors not using generative AI tools. And there is evidence that those clinical doctors who use generative AI made better decisions on their patients. So, at some point, I think it might be unethical not to use it if you prove that the tool enriches your decision making.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
